文献速递重症综合管理与镇静镇痛消化、代谢与肾脏急症心脑血管急症

早期渗透治疗与神经重症患者新发急性肾损伤:MIMIC-IV回顾性队列研究

Early osmotherapy exposure and subsequent incident acute kidney injury in neurocritical care patients: a MIMIC-IV retrospective cohort study.
PubMed 文献 · J Intensive Care · 2026-07-20
一句话结论神经重症患者ICU前48小时接受渗透治疗(甘露醇或高渗盐水)与后续新发AKI风险升高相关(OR 1.48),需加强肾监测,但不能推断因果。

该回顾性队列研究基于MIMIC-IV v3.1,纳入2756例成人神经重症患者,采用48小时landmark设计,排除48小时内已死亡、转出ICU或已发生AKI者。主要暴露为ICU前48小时内任何渗透治疗(甘露醇或高渗盐水),主要终点为48小时后至ICU第7天或出ICU期间新发AKI。624例(22.6%)发生新发AKI,365例(13.2%)接受渗透治疗;双稳健重叠加权logistic模型显示渗透治疗与新发AKI相关(OR 1.48,95%CI 1.12-1.96,P=0.006),改良Poisson模型RR 1.30(95%CI 1.08-1.57)。早期钠负荷和氯负荷在探索性调整模型中未实质性减弱该关联。作者建议对接受临床指征渗透治疗者仔细监测肾功能,但适应证残余混杂限制因果解读。

要点

  • 在48小时landmark时仍存活、留在ICU且无AKI的成人神经重症患者中,前48小时任何渗透治疗(甘露醇或高渗盐水)与后续新发AKI风险升高独立相关(OR 1.48,95%CI 1.12-1.96)。
  • 渗透治疗组后续新发AKI的改良Poisson RR为1.30(95%CI 1.08-1.57,P=0.006),与logistic模型方向一致。
  • 早期血清钠负荷(OR 0.99,95%CI 0.92-1.07)和氯负荷(OR 1.01,95%CI 0.94-1.09)在探索性调整模型中未实质性减弱渗透治疗与AKI的关联。
  • 发生后续AKI的患者医院死亡率更高、ICU和出院时基于肌酐的肾功能恢复更低(探索性临床相关性分析)。
  • 因存在适应证残余混杂,不能将关联解读为因果;但对接受临床指征渗透治疗的神经重症患者应仔细监测肾功能。

适用人群与场景

  • 排除48小时内死亡、转出ICU或已发生AKI的患者;最终48小时landmark队列2756例。
  • 场景为ICU(神经重症),非院前或急诊抢救室。

诊断标准与关键阈值

  • AKI定义原文未明确给出具体标准(如KDIGO分期界值),仅描述为incident AKI;原文未提及具体肌酐或尿量阈值。
  • 主要暴露为ICU前48小时内任何渗透治疗,定义为甘露醇或高渗盐水给药,与无渗透治疗比较。
  • 主要终点为48小时landmark后至ICU第7天或ICU出院期间新发AKI。

处置流程与药物剂量

  • 原文未提及具体渗透治疗药物剂量、浓度、给药途径、频次或疗程;仅定义暴露为甘露醇或高渗盐水。
  • 原文未提及AKI预防或处理的具体流程。
  • 作者结论建议:对接受临床指征渗透治疗的患者进行仔细的肾脏监测(原文未给出具体监测频率或指标)。

红旗征与不能漏的情况

  • 原文未提及需要立刻处理或不能漏诊的具体红旗征及处理措施。
  • 原文提及后续发生AKI的患者医院死亡率更高、基于肌酐的肾功能恢复更低,提示渗透治疗后新发AKI与不良结局相关(探索性分析)。

研究设计与关键结果

  • 研究类型:回顾性队列研究,使用MIMIC-IV version 3.1数据库,单数据库多中心数据(具体中心数原文未提及)。
  • 样本量:最终48小时landmark队列2756例成人神经重症患者;624例(22.6%)在landmark后发生新发AKI;365例(13.2%)接受任何渗透治疗。
  • 主要终点:双稳健重叠加权logistic模型中,任何渗透治疗与后续新发AKI相关(OR 1.48;95%CI 1.12-1.96;P=0.006);双稳健重叠加权改良Poisson估计RR 1.30(95%CI 1.08-1.57;P=0.006)。
  • 钠/氯负荷分析纳入2455例实验室数据完整患者:早期钠负荷OR 0.99(95%CI 0.92-1.07;P=0.792),氯负荷OR 1.01(95%CI 0.94-1.09;P=0.743),在探索性调整模型中未实质性减弱关联。
  • 探索性临床相关性分析:后续发生AKI的患者医院死亡率更高、ICU和出院时基于肌酐的肾功能恢复更低。
  • 剂量代理和高渗盐水浓度特异性分析为探索性,因剂量捕获不完整且23.4%高渗盐水暴露稀疏。

证据类型、等级与局限

  • 证据类型:回顾性队列研究(MIMIC-IV数据库),非RCT。
  • 局限:回顾性设计、适应证残余混杂限制因果解读;剂量捕获不完整;23.4%高渗盐水暴露稀疏使浓度特异性分析仅为探索性;原文未提及单中心或多中心具体数量、开放标签等。

对床旁实践的改变

  • 对神经重症患者接受临床指征的渗透治疗(甘露醇或高渗盐水)时,应加强肾功能监测(原文建议仔细肾脏监测,未给具体方案)。
  • 不能因该关联而拒绝有临床指征的渗透治疗;原文明确残余混杂限制因果解读。
  • 早期血清钠或氯负荷未实质性减弱AKI关联,提示不能仅通过管理钠/氯负荷来消除渗透治疗相关AKI风险(探索性分析)。
  • 适用人群为成人神经重症ICU患者中48小时landmark时存活、在ICU且无AKI者;不适用于48小时内已发生AKI、死亡或转出ICU者,也不适用于非神经重症人群。

指南或共识出处

  • 原文未提及具体指南或共识名称;研究数据来源为MIMIC-IV version 3.1数据库。

以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。

英文原文(摘要)· 点击展开

BACKGROUND: Osmotherapy is frequently used in neurocritical care to manage cerebral edema and intracranial hypertension. However, its association with subsequent new-onset acute kidney injury (AKI), and whether early serum sodium or chloride burden materially attenuates this association, remain uncertain.

METHODS: We conducted a retrospective cohort study using MIMIC-IV version 3.1. Adult first-ICU neurocritical care patients were analyzed with a 48-h landmark design. The primary risk set included patients who were alive, remained in the ICU, and were AKI-free at 48 h after ICU admission. The primary exposure was any osmotherapy, defined as mannitol or hypertonic saline administered within the first 48 ICU hours, compared with no osmotherapy. The primary outcome was incident AKI after the 48-h landmark through ICU day 7 or ICU discharge. Multivariable regression was used as the main adjusted model; propensity-score weighting, overlap weighting, doubly robust models, and modified Poisson regression were used as complementary estimators. Sodium/chloride burden analyses were conducted in the lab-complete subset.

RESULTS: The final 48-h landmark cohort included 2,756 adult neurocritical care patients, of whom 624 (22.6%) developed incident AKI after the landmark. Any osmotherapy was administered to 365 patients (13.2%). In the doubly robust overlap-weighted logistic model, any osmotherapy was associated with subsequent incident AKI (OR, 1.48; 95% CI 1.12-1.96; P = 0.006). The corresponding doubly robust overlap-weighted modified Poisson estimate was RR 1.30 (95% CI 1.08-1.57; P = 0.006). Sodium/chloride burden analyses included 2,455 lab-complete patients. Early sodium burden (OR, 0.99; 95% CI 0.92-1.07; P = 0.792) and chloride burden (OR, 1.01; 95% CI 0.94-1.09; P = 0.743) did not materially attenuate the observed association in exploratory adjustment models. In exploratory clinical relevance analyses, patients with subsequent AKI had higher hospital mortality and lower creatinine-based renal recovery at ICU and hospital discharge. Dose-proxy and hypertonic saline concentration-specific analyses were exploratory because dose capture was incomplete and 23.4% hypertonic saline exposure was sparse.

CONCLUSIONS: Among adult neurocritical care patients who were alive, remained in the ICU, and were AKI-free at the 48-h landmark, early osmotherapy exposure was associated with a higher risk of subsequent incident AKI. This association was not materially attenuated by early serum sodium or chloride burden in exploratory adjustment models. These findings support careful renal monitoring in patients receiving clinically indicated osmotherapy, while residual confounding by indication precludes causal interpretation.

来源:J Intensive Care,查看原文。版权归原作者所有。

参考来源

  1. Du S, Zhang S, Lai W, et al. Early osmotherapy exposure and subsequent incident acute kidney injury in neurocritical care patients: a MIMIC-IV retrospective cohort study. J Intensive Care. 2026. PMID: 42477846. doi:10.1186/s40560-026-00917-z

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。